Hikma expands injectables capacity with acquisition of Xellia's US assets

Hikma, a London-based generics maker, has agreed to acquire parts of Xellia's U.S. assets, including the manufacturing facility in Cleveland. The acquisition will bolster Hikma's U.S. injectable manufacturing capabilities and portfolio, adding significant scale to its operations and complex technologies. This strategic move is part of Hikma's commitment to enhancing its productivity, expanding into the CDMO business, and strengthening its position in the market.